Atrás
54
Rango del Día
$1.63
$1.77
Rango de 52 Semanas
$0.32
$1.83
Volumen
2,672,131
Promedio 50D / 200D
$1.45
/
$1.26
Cierre Anterior
$1.64
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (627 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -14.5 | 0.3 |
| P/B | 6.8 | 2.9 |
| ROE % | -39.7 | 3.7 |
| Net Margin % | -101.1 | 3.8 |
| Rev Growth 5Y % | 259.6 | 10.0 |
| D/E | 0.6 | 0.2 |
Precio Objetivo de Analistas
Hold
$6.00
+248.8%
EPS Futuro
-$0.18
Ingresos Est.
34 M
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2030 |
$0.06
$0.05 – $0.07
|
160 M | 2 |
| FY2029 |
$0.01
$0.01 – $0.01
|
130 M | 2 |
| FY2028 |
-$0.11
-$0.18 – $0.02
|
69 M | 4 |
Insider Trading Activity
Buy ratio (90d)
100.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 28, 2026 |
Granowitz Craig B
SVP, Chief Medical Officer
|
other | 733,650 | — | — |
| Feb 28, 2026 |
Gopinathan Suma
SVP, Discovery
|
other | 224,238 | — | — |
| Feb 28, 2026 |
McDermott Wendy
SVP, Human Resources
|
other | 516,919 | — | — |
| Feb 23, 2026 |
DEBBANE RAYMOND
Director
|
buy | 100,000 | $1.47 | $147,000 |
| Feb 12, 2026 |
Crum Brian T
SVP, General Counsel & Secr.
|
grant | 749,270 | — | — |
| Feb 12, 2026 |
Granowitz Craig B
SVP, Chief Medical Officer
|
grant | 866,530 | — | — |
| Feb 12, 2026 |
Exton Michael
Chief Executive Officer
|
grant | 2,156,110 | — | — |
| Feb 12, 2026 |
Coiante Scott M
SVP, Chief Financial Officer
|
grant | 681,700 | — | — |
| Feb 12, 2026 |
Gopinathan Suma
SVP, Discovery
|
grant | 596,130 | — | — |
| Feb 12, 2026 |
McDermott Wendy
SVP, Human Resources
|
grant | 625,500 | — | — |
| Feb 12, 2026 |
DeFrancesco Lisa
SVP, IR and Corp Comm
|
grant | 643,830 | — | — |
| Jun 3, 2025 |
BARKER SAM L
Director
|
grant | 193,118 | — | — |
| Jun 3, 2025 |
Amouyal Philippe
Director
|
grant | 193,118 | — | — |
| Jun 3, 2025 |
Cheung Ivan
Director
|
grant | 193,118 | — | — |
| Jun 3, 2025 |
SOBECKI CHRISTOPHER J
Director
|
grant | 193,118 | — | — |
| Jun 3, 2025 |
DEBBANE RAYMOND
Director
|
grant | 193,118 | — | — |
| May 13, 2025 |
Swain Judith L
Director
|
other | 73,620 | — | — |
| May 13, 2025 |
BARKER SAM L
Director
|
other | 73,620 | — | — |
| May 13, 2025 |
Sullivan Diane E.
Director
|
other | 73,620 | — | — |
| May 13, 2025 |
Amouyal Philippe
Director
|
other | 73,620 | — | — |
Puntos Clave
Revenue grew 259.55% annually over 5 years — strong growth
Negative free cash flow of -67.85M
PEG of 0.11 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 199.31%
Capital efficient — spends only 0.00% of revenue on capex
Crecimiento
Revenue Growth (5Y)
259.55%
Revenue (1Y)60.24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
-39.72%
ROIC-21.61%
Net Margin-101.08%
Op. Margin-98.21%
Seguridad
Debt / Equity
0.58
Current Ratio4.88
Interest Coverage-5.87
Valoración
P/E Ratio
-14.48
P/B Ratio6.78
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 60.24% | Revenue Growth (3Y) | 543.15% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 259.55% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 49.80M | Net Income (TTM) | -50.34M |
| ROE | -39.72% | ROA | -27.21% |
| Gross Margin | 99.45% | Operating Margin | -98.21% |
| Net Margin | -101.08% | Free Cash Flow (TTM) | -67.85M |
| ROIC | -21.61% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.58 | Current Ratio | 4.88 |
| Interest Coverage | -5.87 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -14.48 | P/B Ratio | 6.78 |
| P/S Ratio | 14.63 | PEG Ratio | 0.11 |
| EV/EBITDA | N/A | Dividend Yield | 0.00% |
| Market Cap | 728.73M | Enterprise Value | 756.64M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 49.80M | 31.08M | 1.20M | 139,000.0 | 298,000.0 |
| Net Income | -50.34M | -200.40M | -177.12M | -101.94M | -87.76M |
| EPS (Diluted) | -0.14 | -0.63 | -0.80 | -0.62 | -0.61 |
| Gross Profit | 49.53M | 30.47M | -57.77M | -52.38M | -54.75M |
| Operating Income | -48.91M | -197.12M | -171.75M | -100.76M | -87.09M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 184.99M | 298.42M | 229.43M | 194.30M | 136.91M |
| Total Liabilities | 77.45M | 152.47M | 136.32M | 77.18M | 23.31M |
| Shareholders' Equity | 107.54M | 145.95M | 93.11M | 117.12M | 113.60M |
| Total Debt | 62.24M | 108.40M | 106.06M | 55.29M | 2.28M |
| Cash & Equivalents | 34.33M | 66.66M | 22.47M | 46.35M | 64.07M |
| Current Assets | 101.90M | 246.19M | 176.55M | 140.87M | 88.92M |
| Current Liabilities | 20.87M | 45.25M | 31.55M | 23.17M | 22.12M |
Puntuaciones de Estrategias
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Full Throttle
#47 of 146
Actividad Reciente
Entró
Full Throttle
Mar 24, 2026